Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Adc Therapeutics Sa (NY: ADCT )

1.990 -0.080 (-3.86%)
Official Closing Price Updated: 4:00 PM EDT, Mar 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Adc Therapeutics Sa

< Previous 1 2 3 Next >
ADC Therapeutics Releases its Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2022
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics to Host Fourth Quarter and Year-End 2022 Financial Results Conference Call on February 28, 2023
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics Announces Pricing of Underwritten Offering by a Selling Shareholder
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics to Participate in February Investor Conferences
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics Appoints Mohamed Zaki as Chief Medical Officer
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics and Sobi Announce European Commission Approval of ZYNLONTA® (loncastuximab tesirine) for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics Appoints Jose Carmona as Chief Financial Officer
From ADC Therapeutics SA
Via Business Wire
Biocytogen Enters into Antibody Agreement with ADC Therapeutics
From Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Via Business Wire
ADC Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics to Participate in the Jefferies London Healthcare Conference
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics Announces Abstracts Accepted for Presentation at the 64th ASH Annual Meeting
From ADC Therapeutics SA
Via Business Wire
IGM Biosciences and ADC Therapeutics Announce Clinical Collaboration Agreement to Evaluate Imvotamab (IGM-2323) in Combination with ZYNLONTA® in Patients with Relapsed or Refractory B Cell Non-Hodgkin’s Lymphoma
From ADC Therapeutics SA
Via Business Wire
IGM Biosciences and ADC Therapeutics Announce Clinical Collaboration Agreement to Evaluate Imvotamab (IGM-2323) in Combination with ZYNLONTA® in Patients with Relapsed or Refractory B Cell Non-Hodgkin’s Lymphoma
From IGM Biosciences, Inc.
Via Globe NewsWire
ADC Therapeutics Appoints Kristen Harrington-Smith as Chief Commercial Officer and Peter Graham as Chief Legal Officer
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics to Host Third Quarter 2022 Financial Results Conference Call on November 8, 2022
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics Announces Abstracts to be Presented at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2022)
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics and Sobi Announce ZYNLONTA® (loncastuximab tesirine) Receives Positive CHMP Opinion in Europe for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
From ADC Therapeutics SA
Via Business Wire
INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in ADC Therapeutics SA with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in ADC Therapeutics SA with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
ADC Therapeutics to Participate in Morgan Stanley’s 20th Annual Global Healthcare Conference
From ADC Therapeutics
Via Business Wire
ADC Therapeutics Announces $175 million Senior Secured Term Loan from Owl Rock and Oaktree and Settlement of Existing Senior Secured Convertible Notes
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics to Host Second Quarter 2022 Financial Results Conference Call on August 9, 2022
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics Doses First Patient in Phase 1b Clinical Trial of ADCT-601 Targeting AXL as a Single Agent and in Combination with Gemcitabine in Advanced Solid Tumors
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) in Combination with Rituximab in First-Line Diffuse Large B-Cell Lymphoma
From ADC Therapeutics SA
Via Business Wire
Overland ADCT BioPharma Announces First Patient Dosed in China with ZYNLONTA® in Combination with Rituximab in Global Phase 3 Clinical Trial
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics Announces Exclusive License Agreement with Sobi to Develop and Commercialize ZYNLONTA® (loncastuximab tesirine-lpyl) in Europe and Select International Territories
From ADC Therapeutics SA
Via Business Wire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.